An FDA decision is expected in spring 2026
GLP-1 receptor agonists, the drug class behind Ozempic, Wegovy, and Mounjaro, have moved from a pharmaceutical story to a commercial one, and the CPS executives who have not yet treated them as a business problem are running out of time to get ahead of them
There is little research focusing on the pathophysiology of acute or chronic pain in SCD, and therefore it is still poorly understood
We thank you for your understanding during this difficult time
Note : While payroll reimbursement is the most common approach, employers can also offer alternative methods such as direct deposit, LSA debit cards, or even shopping directly through an integrated marketplace for eligible products and services
Tip: Rotate injection sites each time to prevent soreness or tissue damage